the Company’s second fatty acid synthase (FASN) inhibitor. TVB-3567 is a potent and selective small molecule FASN inhibitor, ...

Sagimet Biosciences (NASDAQ:SGMT – Get Free Report) is projected to issue its quarterly earnings data before the market opens ...

Sagimet Biosciences Inc. has obtained IND clearance from the FDA for TVB-3567 (ASC-60), a selective small-molecule fatty acid ...

Try Now>> See the top stocks recommended by analysts >> Sagimet Biosciences NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Detailed price information for Sagimet Biosciences Inc Series A (SGMT-Q) from The Globe and Mail including charting and trades.

The presentation will spotlight the company’s lead drug candidate, denifanstat, an oral, once-daily fatty acid synthase (FASN) inhibitor, which has shown promising results in the Phase 2b ...

Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).

Sagimet Biosciences (SGMT) announced the clearance of its Investigational New Drug, IND, application for TVB-3567, the Company’s second fatty ...